AVDL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Avadel completes enrollment in Phase 3 REVITALYZ™ trial for idiopathic hypersomniaDec 18, 2025
- Avadel Pharmaceuticals to present new data on LUMRYZ™ (sodium oxybate) extended-release oral suspension at World Sleep 2025Sep 5, 2025
- Avadel gets FDA Orphan Drug Designation for LUMRYZ™ to treat idiopathic hypersomniaJun 5, 2025
- Avadel Pharmaceuticals to present new data on LUMRYZ (sodium oxybate) extended-release oral suspension at SLEEP 2025May 30, 2025